Evidence map›Paper›PMID 42900306›Full record

SynthesisJournal of gastrointestinal cancer2026

Neoadjuvant Therapy for Gastric Adenocarcinoma with Signet Ring Cells: A Systematic Review and Meta-Analysis.

Evgenia Mela, Maximos Frountzas, Fani Apostolidou Kiouti, Adriani Nikolakopoulou, Anna Bettina Haidich, Dimitrios Schizas, Tania Triantafyllou

Abstract readMeta-AnalysisSystematic Review
PubMed Publisher
In one paragraph

Synthesis in Journal of gastrointestinal cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evgenia MelaFirst Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, Hippocration General Hospital, Vasilissis Sofias 114, Athens, 11527, Greece. evmela@med.uoa.gr.ORCID http://orcid.org/0000-0001-7335-8319
Maximos FrountzasDepartment of Colorectal Surgery, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom.
Fani Apostolidou KioutiDepartment of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Adriani NikolakopoulouDepartment of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Anna Bettina HaidichDepartment of Hygiene, Social-Preventive Medicine & Medical Statistics, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece.
Dimitrios SchizasFirst Department of Surgery, National and Kapodistrian University of Athens, Laiko General Hospital, Athens, Greece.
Tania TriantafyllouFirst Propaedeutic Department of Surgery, National and Kapodistrian University of Athens, Hippocration General Hospital, Vasilissis Sofias 114, Athens, 11527, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSignet ring cell-containing gastric cancer constitutes an increasingly recognized subtype. Although perioperative chemotherapy is the standard of treatment for locally advanced gastric cancer, its efficacy in signet ring cell-containing gastric adenocarcinomas remains controversial. This systematic review and meta-analysis aims to assess the impact of neoadjuvant chemotherapy compared to upfront surgery on overall survival.

methodsA systematic search of MEDLINE, Scopus, and Cochrane was conducted up to January 2026. Eligible studies included adult patients with signet ring cell-containing gastric cancer undergoing neoadjuvant chemotherapy followed by surgery compared to upfront gastrectomy. A random-effects meta-analysis was performed to pool hazard ratios for overall survival.

resultsSix studies, including seven cohorts and 5.388 patients, were included. The pooled analysis demonstrated no significant difference in overall survival between neoadjuvant chemotherapy and upfront surgery (HR 0.96, 95% CI 0.68-1.34, I

conclusionsNeoadjuvant chemotherapy was not associated with a significant improvement in overall survival compared with upfront surgery in signet-ring cell-containing gastric cancer. While perioperative chemotherapy remains the recommended therapeutic approach, further studies employing contemporary chemotherapy regimens are warranted to define its role in this distinct histological subtype.

Indexed as

AdenocarcinomaCarcinoma, Signet Ring CellNeoadjuvant TherapyStomach NeoplasmsChemotherapy, AdjuvantGastrectomyHumansGastric cancerNeoadjuvant chemotherapyNeoadjuvant therapyPerioperative chemotherapySignet ring cellSurgery

Identifiers

PMID42900306

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.